COV Cleo Diagnostics Ltd
Healthcare · Medical Devices
· website
$0.36
52wk 0.31 – 0.90
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$49.36M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.03
Dividend yield
—
Payout ratio
0.0%
Beta
0.36
EV / EBITDA
-9.92
Price / Book
5.62
ROE
-49.6%
Operating margin
-105.8%
Net margin
-157.4%
Total cash
$9.43M
Total debt
$0
Current ratio
8.46
Debt / Equity
—
Free cash flow
$-1.25M
Avg volume
165,349
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income-$5.18M
- Net income-$4.00M
- Diluted EPS-0.03
- Free cash flow-$2.91M
- Net debt-$6.46M